(Reuters) – U.S. biotechnology company Acorda Therapeutics Inc. (ACOR.O) announced on Tuesday an agreed $363 million cash bid for all of the shares in Finland’s Biotie Therapies (BTH1V.HE).
Acorda said the acquisition would expand its pipeline in Parkinson’s disease therapies.
The company will offer 0.294 euros for each Biotie share, a premium of about 95 percent compared with the closing price on Monday.
Biotie shares had jumped 79 percent to 0.27 euros by 0824 GMT (3.24 a.m. ET).
(Reporting by Tuomas Forsell; Editing by Jussi Rosendahl and Mark Potter)
Johnson Matthey Plc (JM; London) announced that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consideration of US$700 million (£550 million) on a cash free debt free basis.
Lonza AG (Basel, Switzerland) announced it has signed an agreement to acquire the Genentech large-scale biologics manufacturing site in Vacaville, Calif. from Roche (Basel, Switzerland) for $1.2 billion. The acquisition will significantly increase Lonza’s large-scale biologics manufacturing capacity.
Roquette plans to acquire International Flavors & Fragrances (IFF) Pharma Solutions for an enterprise value of up to €2.85 billion (US$3.09 billion). With the acquisition set to close in the first half of 2025, the plant-based ingredient and pharmaceutical excipients supplier aims to reinforce its position in the pharmaceutical industry.